Ukinuta odobrenja, povlačenje serija lijekova, pisma zdravstvenim radnicima i novi lijekovi EU — svakodnevno, automatski. Zadnje ažuriranje: 13. 11. 2026. 08:55
Izvori: promjene pratimo na temelju informacija Agencije za lijekove i medicinske proizvode (HALMED) — rješenja o ukidanju odobrenja, obavijesti o povlačenju serija i pisma zdravstvenim radnicima. Odluke o centralizirano odobrenim lijekovima dolaze iz registra Unije Europske komisije (oznaka EU). Nestašice i liste lijekova HZZO-a ovdje (još) nisu uključene.
br. EU/1/14/941 · odobreno 22. 8. 2014. · This medicinal product is for diagnostic use only.
VIZAMYL is a radiopharmaceutical indicated for Positron Em… · GE Healthcare AS · flutemetamol (18F) · ATC V09AX04
br. EU/1/15/1079 · odobreno 15. 2. 2016. · Vaxelis (DTaP-HB-IPV-Hib) is indicated for primary and booster vaccination in infants and toddlers from the ag… · MCM Vaccine B.V. · Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed) · ATC J07CA09
br. EU/1/25/1947 · odobreno 28. 7. 2025. · RIULVY is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing … · Neuraxpharm Pharmaceuticals, S.L. · Tegomil fumarate · ATC L04AX10
br. EU/1/23/1730 · odobreno 31. 5. 2023. · Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with… · Neuraxpharm Pharmaceuticals, S.L. · ublituximab · ATC L04AG14
br. EU/1/10/638 · odobreno 27. 7. 2010. · OZURDEX is indicated for the treatment of adult patients with:
• Visual impairment due to diabetic macular oe… · AbbVie Deutschland GmbH & Co. KG · dexamethasone · ATC S01BA01
br. EU/1/23/1732 · odobreno 31. 5. 2023. · Lacosamide Adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secon… · Extrovis EU Kft. · lacosamide · ATC N03AX18
br. EU/1/15/1064 · odobreno 16. 12. 2015. · Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly me… · Amgen Europe B.V. · talimogene laherparepvec · ATC L01XL02
br. EU/1/25/2006 · odobreno 12. 2. 2026. · Aumseqa as monotherapy is indicated for:
• the first line treatment of adult patients with advanced non small… · SFL Pharmaceuticals Deutschland GmbH · aumolertinib · ATC L01EB11
Lekoskop